These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21251901)

  • 21. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
    Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
    Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.
    Chen CY; Liu HJ; Tsai CP; Chung CY; Shih YS; Chang PC; Chiu YT; Hu YC
    Vaccine; 2010 Nov; 28(48):7644-51. PubMed ID: 20883735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Sato A; Coban C; Ishii KJ
    Vaccine; 2014 May; 32(25):3004-9. PubMed ID: 24721532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes.
    Rosenkrands I; Vingsbo-Lundberg C; Bundgaard TJ; Lindenstrøm T; Enouf V; van der Werf S; Andersen P; Agger EM
    Vaccine; 2011 Aug; 29(37):6283-91. PubMed ID: 21722683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
    Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
    J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
    Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
    Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.